United States Prime Editing and CRISPR Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Prime Editing and CRISPR Market is estimated to grow at a CAGR of 24.1% during the forecast period (2024-2031).

Key Development:

United States: Recent Industry Developments

✅ July 2025 - Prime Medicine announced an additional investment of up to $24 million from the Cystic Fibrosis Foundation to advance gene editing therapy targeting the G542X mutation, a prevalent cystic fibrosis-causing mutation with no current therapies.

✅ July 2025 - CRISPR Therapeutics reported positive Phase 1 data for CTX310, a gene-editing therapy targeting ANGPTL3 to treat hypercholesterolemia, demonstrating significant reductions in LDL-C levels.

✅ May 2025 - Prime Medicine initiated a Phase 1/2 clinical trial of PM359 for Chronic Granulomatous Disease (CGD), marking the first human application of prime editing.

Japan: Recent Industry Developments

✅ July 2025 - Toshiba Energy Systems began operations of its 20 MW alkaline electrolyzer at a hydrogen production site in Fukushima, using surplus renewable energy from local solar and wind farms to supply hydrogen for fuel cell vehicles and power generation.

✅ May 2025 - Japan's National Institute of Allergy and Infectious Diseases commenced a Phase 1/2 trial using base editing to treat X-linked Severe Combined Immunodeficiency (X-SCID), aiming to correct IL2RG gene mutations in immune stem cells.

✅ May 2025 - Mitsubishi Power partnered with Chiyoda Corporation to integrate large-scale electrolyzers with offshore wind projects, aiming to produce green hydrogen for export under Japan's clean energy diplomacy strategy.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/prime-editing-and-crispr-market?sb

Recent Mergers and Acquisitions:

United States: Recent M&A Developments

✅ July 2025 - BlackRock acquired over 3.3 million shares of CRISPR Therapeutics, increasing its stake to approximately 6.9% of the company, reflecting strong institutional interest in gene-editing technologies.

✅ July 2025 - Cathie Wood's ARK Investment Management purchased shares in Prime Medicine, signaling confidence in the company's prime editing platform and its potential for future growth.

✅ June 2025 - Eli Lilly announced its acquisition of Verve Therapeutics for up to $1.3 billion. This strategic move aims to bolster Lilly's pipeline with CRISPR-based therapies targeting cardiovascular diseases, including a promising PCSK9 gene-editing treatment.

Japan: Recent M&A Developments

✅ March 2025 - GenScript Biotech signed a licensing agreement with the Broad Institute of MIT and Harvard to access prime editing technology, enhancing its gene-editing capabilities and expanding its research and development portfolio.

Key Players:

=> Beam Therapeutics, GenScript Biotech, Horizon Discovery, Integrated DNA Technologies, Inscripta, Precision Bioscience, ThermoFisher Scientific Inc, Lonza among others.

Growth Forecast Projected:

The Global Prime Editing and CRISPR Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Prime Editing and CRISPR Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=prime-editing-and-crispr-market

Key Segments:

➥ By Service: Cell Line Engineering, Genome Regulation, Gene Editing, Gene-Modified Cell Therapy

➥ By Application: Biomedical Research & Therapy, Agricultural Research, Others

➥ By End-User: Academic Institutes, Biotechnology & Pharma Companies, Contract Research Organizations, Others

Regional Analysis for Prime Editing and CRISPR Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Prime Editing and CRISPR producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Prime Editing and CRISPR revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/prime-editing-and-crispr-market?sb

FAQ

Q: What is the growth rate of the Prime Editing and CRISPR Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 24.1% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.